FDA lets Guidant widen HF (heart failure) device market
This article was originally published in Clinica
Executive Summary
The US FDA has given Guidant the green-light to broaden the indication for its cardiac resynchronisation therapy defibrillators (CRT-Ds) for heart failure (HF), a move that allows the devices to be made available to thousands more patients.